Background: Crude extract of breadfruit has been reported to have antitumor activity against various cancer cell lines with unknown mechanism.
Purpose: This study aims to investigate the proapoptotic effect of cyclocommunol (CYC), a prenylflavonoid from breadfruit, in two oral squamous cell carcinoma (OSCC) cell lines, SCC2095 and Ca922.
Methods: The antiproliferative effects of CYC were assessed by MTT assays and PI/annexin V analysis. SCC2095 cells were transiently transfected with Mcl-1 plasmid in overexpression experiment. Other methods used to investigate the mechanism of CYC included Western blotting, acridine orange staining and confocal microscopic visualization.
Results: Our results showed that CYC suppressed the viability of SCC2095 and Ca922 with IC values at 48 h of 4.2 and 5.0 µM, respectively. This decrease in viability occurred in a caspase-dependent apoptotic manner. In addition, CYC down-regulated the phosphorylation/expression of Akt/mTOR and Mcl-1, accompanied by reactive oxygen species generation, and autophagy induction. Notably, overexpression of Mcl-1 using Mcl-1-tag-myc partially rescued CYC-mediated caspase-3 activation, PARP cleavage, and cytotoxicity. In summary, our study demonstrated the proapoptotic activity of CYC on OSCC, partially through down-regulation of Mcl-1.
Conclusion: CYC from breadfruit has translational value as a proapoptotic agent for OSCC.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.phymed.2017.12.004 | DOI Listing |
Photodiagnosis Photodyn Ther
December 2024
Dentistry Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Introduction: Squamous cell carcinoma (SCC) is the most common malignancy of the head and neck region. Combination therapy potentially enhances the effectiveness beyond that of each treatment alone. This study aimed to assess whether photodynamic therapy (PDT), using methylene blue as a photosensitizer in conjunction with doxorubicin, produces synergistic effects on the apoptosis of the oral squamous cell carcinoma (OSCC) cell line.
View Article and Find Full Text PDFBackground: The use of liquid biopsy of total cell-free DNA (cfDNA) to identify otherwise undetectable cancers has attracted interest; however, its efficacy remains unknown. We explored whether analysis using total cfDNA is efficacious for Japanese patients with oral squamous cell carcinoma (OSCC).
Methods: We collected total cfDNA from nine patients with OSCC preoperatively, 1 month postoperatively, and every 3 months thereafter to analyze this association.
Head Neck
December 2024
Head and Neck Unit, The Royal Marsden Hospital, London, UK.
Background: To investigate the management of recurrent head and neck squamous cell carcinoma (rHNSCC) and describe survival outcomes.
Methods: Post hoc subgroup analysis of a retrospective national observational cohort was conducted. All patients with rHNSCC who received a definitive treatment decision between September 1, 2021 and November 30, 2021 were included.
Int J Oral Maxillofac Surg
December 2024
Department of Head and Neck Tumors, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.
Oral squamous cell carcinoma (OSCC) is the most common type of head and neck cancer. The development and progression of OSCC are closely linked to various aetiological factors. Early signs of OSCC may manifest as oral lesions, genetic abnormalities, and chronic inflammation.
View Article and Find Full Text PDFOral Surg Oral Med Oral Pathol Oral Radiol
December 2024
Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Shihezi University, Shihezi, China. Electronic address:
Objective: Oral squamous cell carcinoma (OSCC) is a prevalent cancer of the head and neck region. However, the potential role of RCN2 in OSCC is currently not well understood.
Study Design: A series of molecular biology experiments were conducted to explore the mechanism by which RCN2 promotes OSCC growth through protein kinase A (PKA).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!